Autolus, a biotechnology firm focusing on oncology treatments through engineering T-Cells, has launched out of University College London with a £30m ($45m) series A round.
Syncona Partners, the Wellcome Trust’s £200m healthcare-focused evergreen fund, backed the round. Autolus will be focusing on the development and commercialisation of immunotherapies developed at the university. Similar to other disruptive oncology firms such as Juno Therapeutics, Kite Pharma, and Adaptimmune, Autolus is looking to utilise engineered T-Cells to target tumours.
Christian Itin,…